Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 317

1.

The value of ¹⁸F-FDG PET/CT in the management of malignant peripheral nerve sheath tumors.

Khiewvan B, Macapinlac HA, Lev D, McCutcheon IE, Slopis JM, Al Sannaa G, Wei W, Chuang HH.

Eur J Nucl Med Mol Imaging. 2014 Sep;41(9):1756-66. doi: 10.1007/s00259-014-2756-0. Epub 2014 Apr 4.

PMID:
24699907
2.

Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis on Preoperative ¹⁸F-FDG PET/CT in Patients with Pancreatic Cancer.

Lee JW, Kang CM, Choi HJ, Lee WJ, Song SY, Lee JH, Lee JD.

J Nucl Med. 2014 Jun;55(6):898-904. doi: 10.2967/jnumed.113.131847. Epub 2014 Apr 7.

3.

Combined pre-treatment MRI and 18F-FDG PET/CT parameters as prognostic biomarkers in patients with cervical cancer.

Miccò M, Vargas HA, Burger IA, Kollmeier MA, Goldman DA, Park KJ, Abu-Rustum NR, Hricak H, Sala E.

Eur J Radiol. 2014 Jul;83(7):1169-76. doi: 10.1016/j.ejrad.2014.03.024. Epub 2014 Mar 30.

PMID:
24767630
4.

Prognostic significance of preoperative metabolic tumour volume and total lesion glycolysis measured by (18)F-FDG PET/CT in squamous cell carcinoma of the oral cavity.

Ryu IS, Kim JS, Roh JL, Cho KJ, Choi SH, Nam SY, Kim SY.

Eur J Nucl Med Mol Imaging. 2014 Mar;41(3):452-61. doi: 10.1007/s00259-013-2571-z. Epub 2013 Oct 1.

PMID:
24081448
5.

Predictive value of pre-therapy (18)F-FDG PET/CT for the outcome of (18)F-FDG PET-guided radiotherapy in patients with head and neck cancer.

Picchio M, Kirienko M, Mapelli P, Dell'Oca I, Villa E, Gallivanone F, Gianolli L, Messa C, Castiglioni I.

Eur J Nucl Med Mol Imaging. 2014 Jan;41(1):21-31. doi: 10.1007/s00259-013-2528-2. Epub 2013 Aug 29.

PMID:
23990143
6.

FDG PET/CT metabolic tumor volume and total lesion glycolysis predict prognosis in patients with advanced lung adenocarcinoma.

Chung HW, Lee KY, Kim HJ, Kim WS, So Y.

J Cancer Res Clin Oncol. 2014 Jan;140(1):89-98. doi: 10.1007/s00432-013-1545-7. Epub 2013 Nov 6.

PMID:
24194352
7.

Total lesion glycolysis by 18F-FDG PET/CT is a reliable predictor of prognosis in soft-tissue sarcoma.

Choi ES, Ha SG, Kim HS, Ha JH, Paeng JC, Han I.

Eur J Nucl Med Mol Imaging. 2013 Dec;40(12):1836-42. doi: 10.1007/s00259-013-2511-y. Epub 2013 Jul 24.

PMID:
23880967
8.

Volume-based parameters measured by using FDG PET/CT in patients with stage I NSCLC treated with stereotactic body radiation therapy: prognostic value.

Satoh Y, Onishi H, Nambu A, Araki T.

Radiology. 2014 Jan;270(1):275-81. doi: 10.1148/radiol.13130652. Epub 2013 Oct 28.

PMID:
24029640
9.

The role of metabolic tumor volume and total lesion glycolysis on ¹⁸F-FDG PET/CT in the prognosis of epithelial ovarian cancer.

Lee JW, Cho A, Lee JH, Yun M, Lee JD, Kim YT, Kang WJ.

Eur J Nucl Med Mol Imaging. 2014 Oct;41(10):1898-906. doi: 10.1007/s00259-014-2803-x. Epub 2014 May 23.

PMID:
24852188
10.

Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.

Zhang H, Wroblewski K, Liao S, Kampalath R, Penney BC, Zhang Y, Pu Y.

Acad Radiol. 2013 Jan;20(1):32-40. doi: 10.1016/j.acra.2012.07.002. Epub 2012 Sep 19.

PMID:
22999369
11.

Prognostic significance of volume-based FDG PET/CT parameters in patients with locally advanced pancreatic cancer treated with chemoradiation therapy.

Choi HJ, Lee JW, Kang B, Song SY, Lee JD, Lee JH.

Yonsei Med J. 2014 Nov;55(6):1498-506. doi: 10.3349/ymj.2014.55.6.1498.

12.

Metabolic Tumor Volume on 18F-FDG PET/CT Improves Preoperative Identification of High-Risk Endometrial Carcinoma Patients.

Husby JA, Reitan BC, Biermann M, Trovik J, Bjørge L, Magnussen IJ, Salvesen ØO, Salvesen HB, Haldorsen IS.

J Nucl Med. 2015 Aug;56(8):1191-8. doi: 10.2967/jnumed.115.159913. Epub 2015 Jun 4.

13.

Prognostic significance of standardized uptake value and metabolic tumour volume on ¹⁸F-FDG PET/CT in oropharyngeal squamous cell carcinoma.

Kim JW, Oh JS, Roh JL, Kim JS, Choi SH, Nam SY, Kim SY.

Eur J Nucl Med Mol Imaging. 2015 Aug;42(9):1353-61. doi: 10.1007/s00259-015-3051-4. Epub 2015 Jun 12.

PMID:
26067088
14.

Volume-based assessment by (18)F-FDG PET/CT predicts survival in patients with stage III non-small-cell lung cancer.

Hyun SH, Ahn HK, Kim H, Ahn MJ, Park K, Ahn YC, Kim J, Shim YM, Choi JY.

Eur J Nucl Med Mol Imaging. 2014 Jan;41(1):50-8. doi: 10.1007/s00259-013-2530-8. Epub 2013 Aug 16.

PMID:
23948859
15.

Prognostic value of metabolic tumor volume and total lesion glycolysis from ¹⁸F-FDG PET/CT in patients undergoing stereotactic body radiation therapy for stage I non-small-cell lung cancer.

Vu CC, Matthews R, Kim B, Franceschi D, Bilfinger TV, Moore WH.

Nucl Med Commun. 2013 Oct;34(10):959-63. doi: 10.1097/MNM.0b013e32836491a9.

PMID:
23921784
16.

Metabolic parameters using ¹⁸F-FDG PET/CT correlate with occult lymph node metastasis in squamous cell lung carcinoma.

Kim DH, Song BI, Hong CM, Jeong SY, Lee SW, Lee J, Ahn BC.

Eur J Nucl Med Mol Imaging. 2014 Nov;41(11):2051-7. doi: 10.1007/s00259-014-2831-6. Epub 2014 Jul 3.

PMID:
24990401
17.

Metabolic tumour burden assessed by ¹⁸F-FDG PET/CT associated with serum CA19-9 predicts pancreatic cancer outcome after resection.

Xu HX, Chen T, Wang WQ, Wu CT, Liu C, Long J, Xu J, Zhang YJ, Chen RH, Liu L, Yu XJ.

Eur J Nucl Med Mol Imaging. 2014 Jun;41(6):1093-102. doi: 10.1007/s00259-014-2688-8. Epub 2014 Feb 13.

PMID:
24522797
18.

Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.

Liao S, Penney BC, Wroblewski K, Zhang H, Simon CA, Kampalath R, Shih MC, Shimada N, Chen S, Salgia R, Appelbaum DE, Suzuki K, Chen CT, Pu Y.

Eur J Nucl Med Mol Imaging. 2012 Jan;39(1):27-38. doi: 10.1007/s00259-011-1934-6. Epub 2011 Sep 23.

PMID:
21946983
19.

Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis measured by 18F-FDG PET/CT in salivary gland carcinomas.

Ryu IS, Kim JS, Roh JL, Lee JH, Cho KJ, Choi SH, Nam SY, Kim SY.

J Nucl Med. 2013 Jul;54(7):1032-8. doi: 10.2967/jnumed.112.116053. Epub 2013 May 13.

20.

Prospective evaluation of qualitative and quantitative ¹⁸F-FDG PET-CT parameters for predicting survival in recurrent carcinoma of the cervix.

Maharjan S, Sharma P, Patel CD, Sharma DN, Dhull VS, Jain SK, Thulkar S, Malhotra A, Kumar R.

Nucl Med Commun. 2013 Aug;34(8):741-8. doi: 10.1097/MNM.0b013e3283622f0d.

PMID:
23676840
Items per page

Supplemental Content

Write to the Help Desk